Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification

George J Netto¹, Mahul B Amin², Eva M Compérat³, Anthony J Gill⁴, Arndt Hartmann⁵, Holger Moch⁶, Santosh Menon⁷, Maria R Raspollini⁸, Mark A Rubin⁹, John R Srigley¹⁰, Puay Hoon Tan¹¹, Satish K Tickoo¹², Toyonori Tsuzuki¹³, Samra Turajlic¹⁴, Ian Cree¹⁵, Daniel M Berney¹⁶

Affiliations

¹ Department of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: gnetto@uabmc.edu.
² Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA; Department of Urology, USC Keck School of Medicine, Los Angeles, CA, USA.
³ Department of Pathology, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria.
⁴ Sydney Medical School, University of Sydney, Sydney, Australia; NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, Australia; Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia.
⁵ Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
⁶ Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
⁷ Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
⁸ Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Italy.
⁹ Department for BioMedical Research, Bern Center for Precision Medicine, University of Bern and Inselspital, Bern, Switzerland.
¹⁰ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
¹¹ Division of Pathology, Singapore General Hospital, Singapore.
¹² Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹³ Department of Surgical Pathology, Aichi Medical University Hospital, Nagakut, Japan.
¹⁴ Francis Crick Institute and Royal Marsden NHS Foundation Trust, London, UK.
¹⁵ International Agency for Research on Cancer, World Health Organization, Lyon, France.
¹⁶ Barts Cancer Institute, Queen Mary University of London and Department of Cellular Pathology, Barts Health NHS Trust, London, UK.

PMID: 36202687
DOI: 10.1016/j.eururo.2022.09.015

Editorial

Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification

George J Netto et al. Eur Urol. 2023 Apr.

. 2023 Apr;83(4):301-303.

doi: 10.1016/j.eururo.2022.09.015. Epub 2022 Oct 4.

Authors

Affiliations

¹ Department of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: gnetto@uabmc.edu.
² Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA; Department of Urology, USC Keck School of Medicine, Los Angeles, CA, USA.
³ Department of Pathology, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria.
⁴ Sydney Medical School, University of Sydney, Sydney, Australia; NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, Australia; Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia.
⁵ Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
⁶ Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
⁷ Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
⁸ Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Italy.
⁹ Department for BioMedical Research, Bern Center for Precision Medicine, University of Bern and Inselspital, Bern, Switzerland.
¹⁰ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
¹¹ Division of Pathology, Singapore General Hospital, Singapore.
¹² Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹³ Department of Surgical Pathology, Aichi Medical University Hospital, Nagakut, Japan.
¹⁴ Francis Crick Institute and Royal Marsden NHS Foundation Trust, London, UK.
¹⁵ International Agency for Research on Cancer, World Health Organization, Lyon, France.
¹⁶ Barts Cancer Institute, Queen Mary University of London and Department of Cellular Pathology, Barts Health NHS Trust, London, UK.

PMID: 36202687
DOI: 10.1016/j.eururo.2022.09.015

Abstract

We present the rationale for keeping the "cancer" label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.

PubMed Disclaimer

Comment in

Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm.
Vickers AJ, Cooperberg MR, Eggener SE. Vickers AJ, et al. Eur Urol. 2023 Apr;83(4):304-306. doi: 10.1016/j.eururo.2022.10.001. Epub 2022 Oct 21. Eur Urol. 2023. PMID: 36280498 No abstract available.
Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015.
Cimadamore A, Lopez-Beltran A, Cheng L, Montironi R. Cimadamore A, et al. Eur Urol. 2023 Mar;83(3):e84-e86. doi: 10.1016/j.eururo.2022.11.024. Epub 2022 Dec 12. Eur Urol. 2023. PMID: 36517350 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification

Affiliations

Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification

Authors

Affiliations

Abstract

Comment in

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical